Frontiers in Cell and Developmental Biology (Jul 2021)
The Second Oncogenic Hit Determines the Cell Fate of ETV6-RUNX1 Positive Leukemia
- Guillermo Rodríguez-Hernández,
- Guillermo Rodríguez-Hernández,
- Ana Casado-García,
- Ana Casado-García,
- Marta Isidro-Hernández,
- Marta Isidro-Hernández,
- Daniel Picard,
- Javier Raboso-Gallego,
- Javier Raboso-Gallego,
- Silvia Alemán-Arteaga,
- Silvia Alemán-Arteaga,
- Alberto Orfao,
- Alberto Orfao,
- Oscar Blanco,
- Oscar Blanco,
- Susana Riesco,
- Susana Riesco,
- Pablo Prieto-Matos,
- Pablo Prieto-Matos,
- Francisco Javier García Criado,
- Francisco Javier García Criado,
- María Begoña García Cenador,
- María Begoña García Cenador,
- Hanno Hock,
- Tariq Enver,
- Isidro Sanchez-Garcia,
- Isidro Sanchez-Garcia,
- Carolina Vicente-Dueñas,
- Carolina Vicente-Dueñas
Affiliations
- Guillermo Rodríguez-Hernández
- Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain
- Guillermo Rodríguez-Hernández
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Ana Casado-García
- Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain
- Ana Casado-García
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Marta Isidro-Hernández
- Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain
- Marta Isidro-Hernández
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Daniel Picard
- Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
- Javier Raboso-Gallego
- Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain
- Javier Raboso-Gallego
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Silvia Alemán-Arteaga
- Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain
- Silvia Alemán-Arteaga
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Alberto Orfao
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Alberto Orfao
- Servicio de Citometría, Departamento de Medicina, CIBERONC (CB16/12/00400), and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain
- Oscar Blanco
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Oscar Blanco
- Departamento de Anatomía Patológica, Universidad de Salamanca, Salamanca, Spain
- Susana Riesco
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Susana Riesco
- Department of Pediatrics, Hospital Universitario de Salamanca, Salamanca, Spain
- Pablo Prieto-Matos
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Pablo Prieto-Matos
- Department of Pediatrics, Hospital Universitario de Salamanca, Salamanca, Spain
- Francisco Javier García Criado
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Francisco Javier García Criado
- Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain
- María Begoña García Cenador
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- María Begoña García Cenador
- Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain
- Hanno Hock
- Cancer Center and Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, and Harvard Stem Cell Institute, Boston, MA, United States
- Tariq Enver
- Department of Cancer Biology, UCL Cancer Institute, University College London, London, United Kingdom
- Isidro Sanchez-Garcia
- Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain
- Isidro Sanchez-Garcia
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Carolina Vicente-Dueñas
- Institute for Biomedical Research of Salamanca, Salamanca, Spain
- Carolina Vicente-Dueñas
- Department of Pediatrics, Hospital Universitario de Salamanca, Salamanca, Spain
- DOI
- https://doi.org/10.3389/fcell.2021.704591
- Journal volume & issue
-
Vol. 9
Abstract
ETV6-RUNX1 is almost exclusively associated with childhood B-cell acute lymphoblastic leukemia (B-ALL), but the consequences of ETV6-RUNX1 expression on cell lineage decisions during B-cell leukemogenesis are completely unknown. Clinically silent ETV6-RUNX1 preleukemic clones are frequently found in neonatal cord blood, but few carriers develop B-ALL as a result of secondary genetic alterations. The understanding of the mechanisms underlying the first transforming steps could greatly advance the development of non-toxic prophylactic interventions. Using genetic lineage tracing, we examined the capacity of ETV6-RUNX1 to instruct a malignant phenotype in the hematopoietic lineage by cell-specific Cre-mediated activation of ETV6-RUNX1 from the endogenous Etv6 gene locus. Here we show that, while ETV6-RUNX1 has the propensity to trigger both T- and B-lymphoid malignancies, it is the second hit that determines tumor cell identity. To instigate leukemia, both oncogenic hits must place early in the development of hematopoietic/precursor cells, not in already committed B-cells. Depending on the nature of the second hit, the resulting B-ALLs presented distinct entities that were clearly separable based on their gene expression profiles. Our findings give a novel mechanistic insight into the early steps of ETV6-RUNX1+ B-ALL development and might have major implications for the potential development of ETV6-RUNX1+ B-ALL prevention strategies.
Keywords